MolMed focuses on the development of therapeutics for treating cancer. The company provides services and processes for human molecular medicine clinical trials and is involved in the manufacture of biological products. The company has developed a platform technology for treating the development of gene and cell therapy products and uses viral vectors for transferring therapeutic genes and cell-marking genes to allow the selection of genetically modified cells and suicide genes into human cells and also specializes in the design and development of vascular targeting agents.